Zypine

Quick links to important sections

Zypine

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zypine

Quick Facts

Property Description
Active Ingredient Olanzapine
Primary Form Oral Tablet (Standard and Orally Disintegrating)
Pharmacological Class Atypical Antipsychotic (Second-Generation)
General Purpose Management of psychotic and severe mood symptoms
Origin Synthetic (Manufactured)

Defining Zypine: Unique Identity and Class

Zypine is a prescription-only medicine (Rx status) that contains the active ingredient olanzapine, which is formally classified as an atypical antipsychotic. As a second-generation antipsychotic, olanzapine is clinically recognized for its effectiveness in managing chronic mental illnesses. This substance is a synthetic compound, manufactured through chemical processes rather than being derived from natural sources.

Zypine is distinctive in that it is available not only as a standard film-coated tablet but also as an Orally Disintegrating Tablet (ODT), offering an alternative form for patients who may find swallowing tablets difficult.


Primary Therapeutic Use of Zypine

The primary goal of Zypine therapy is the stabilization and management of severe mental health conditions. Its therapeutic purpose is focused on controlling the symptoms associated with disorders such as schizophrenia and the manic episodes of Bipolar I Disorder. Its role as a psychotropic agent is to help stabilize mood and improve disordered thought patterns.


Zypine’s Composition

Zypine is comprised of the active ingredient olanzapine and various inactive ingredients (excipients). These inactive substances are essential for creating a stable dosage form, ensuring the correct release of olanzapine, and facilitating reliable absorption in the body. The specific excipients used, such as mannitol in the ODT formulation, distinguish it from a standard tablet and ensure its unique delivery method.

Regulatory References

  1. National Library of Medicine (MedlinePlus)
  2. NIH StatPearls Monograph

What side effects are possible with Zypine?

Possible Side Effects and Safety Information

The official safety profile for Zypine (olanzapine) is structured by regulatory authorities to classify potential reactions and outline mandated safety warnings. These classifications categorize adverse effects by how often they occur and the body system affected, ensuring clarity in the medicine's risk map.

Frequency-Classified Adverse Reactions

The most commonly documented reactions concern metabolism and the nervous system. Adverse effects classified as Very Common (occurring in ge 10%) include somnolence, weight gain, and increases in blood glucose, cholesterol, and triglyceride levels. Effects classified as Common (occurring in ge 1% to < 10%) include dizziness, akathisia (inner restlessness), tremor, constipation, and postural hypotension (dizziness upon standing).

Serious Adverse Reactions (SARs)

Government regulatory documents highlight several serious safety considerations. These include the risk of Neuroleptic Malignant Syndrome (NMS) and the potential for Tardive Dyskinesia (TD). Furthermore, the label mandates warnings for severe hyperglycemia and diabetes mellitus which can, in rare cases, lead to ketoacidosis or coma. Hematological risks like Leukopenia and Neutropenia are also officially documented as serious adverse reactions.

Population-Specific Safety Constraints

The medicine is not approved for the treatment of elderly patients with dementia-related psychosis due to a documented increased risk of death and cerebrovascular events. Adolescent patients exhibit a greater magnitude of weight gain and higher increases in lipid and prolactin levels compared to adults. The safety profile also notes that orthostatic hypotension may be more prominent during the initial dose titration period.

Overdose and Emergency Response

Zypine Overdose and When to Seek Help — Official Regulatory Information

The official regulatory profile for Zypine overdose specifies a range of clinical manifestations, primarily affecting the Central Nervous System, Cardiovascular System, and Neuromuscular System. Documented presentations include a reduced level of consciousness, spanning from drowsiness and sedation to coma, along with signs such as a fast heartbeat (tachycardia), slurred speech (dysarthria), and various Extrapyramidal Symptoms (EPS).

Overdose carries the risk of serious or life-threatening outcomes, including seizures, cardiac arrhythmias, cardiopulmonary arrest, and potential for Neuroleptic Malignant Syndrome (NMS) or acute muscle toxicity.

Mandated Emergency Action: Immediate medical attention must be sought for any suspected overdose. Contact emergency services immediately if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Since no specific antidote is known for Zypine, management is focused on providing symptomatic and supportive treatment. This includes establishing and maintaining an airway, ensuring adequate oxygenation and ventilation, and continuous medical supervision. The regulatory documents note that administration of activated charcoal may be considered if given soon after ingestion.

Therapeutic Uses of Zypine

What Zypine treats: Main Uses and Benefits

Zypine (olanzapine) is generally used for managing symptoms related to heightened physiological activity and systemic imbalance across therapeutic domains. Its therapeutic areas include conditions characterized by periods of heightened symptoms such as Schizophrenia, acute manic or mixed episodes of Bipolar I Disorder, and Treatment-Resistant Depression when used in combination therapy. It is applied in clinical settings that involve acute or unstable symptom patterns, particularly when symptoms may interfere with daily functioning.

It is commonly used to help with symptom clusters that may become intense or disruptive, such as delusions, hallucinations, severe irritability, and manic hyperactivity. This therapeutic support helps ease the overall symptom burden, assisting with maintaining functional stability to address the risk of symptomatic recurrence. Zypine contributes to improved comfort during symptomatic periods, supporting patients during difficult episodes by easing distress.

Property Therapeutic Focus
Quick Fact: Relief for Psychotic and Manic Symptom Clusters

Regulatory References

  1. DailyMed - NIH/NLM

Eligibility and Restrictions for Use

The eligibility for Zypine (olanzapine) is defined by official regulatory labeling, outlining specific populations who are permitted, restricted, or prohibited from using the medicine.

Contraindications and Restrictions

Classification Eligibility Entity/Restriction
Contraindicated Patients with known hypersensitivity to olanzapine or its components.
Contraindicated Patients with known risk factors for narrow-angle glaucoma.
Not Approved/Not Recommended Elderly patients with dementia-related psychosis (due to increased risk of death and stroke).
Use with Caution Conditions aggravated by anticholinergic effects, such as prostatic hypertrophy or paralytic ileus.

Age and Physiological Eligibility

Age-Related Rules: Use is established for adults and adolescents aged 13 years and older in the U.S. for approved indications. However, some regulators do not recommend use in children and adolescents under 18 years due to insufficient safety and efficacy data. Safety and effectiveness have not been established in children under 13.

Organ Function: Use requires caution in patients with hepatic impairment (moderate liver insufficiency) or severe renal impairment; a lower starting dose should be considered in these populations.

Reproductive Status: Breastfeeding is not recommended while taking Zypine. Use during the third trimester of pregnancy carries a risk of extrapyramidal and/or withdrawal symptoms in the newborn.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define Zypine's (olanzapine) interaction profile based on pharmacokinetic (PK) and pharmacodynamic (PD) effects, detailing specific substance-related constraints. The primary PK interaction involves metabolic clearance through the CYP1A2 enzyme pathway. Co-administration with strong CYP1A2 inhibitors, such as Fluvoxamine, decreases olanzapine clearance, resulting in increased systemic exposure. Conversely, CYP1A2 inducers like Carbamazepine and cigarette smoking significantly increase clearance, thus decreasing olanzapine blood levels.

PD interactions are defined by additive effects. Co-administration with alcohol or other CNS Acting Drugs may potentiate effects such as sedation and orthostatic hypotension. Combining Zypine with Serotonergic Agents carries the potential for Serotonin Syndrome. Procedural restrictions strictly prohibit the co-administration of intramuscular olanzapine with parenteral benzodiazepines. For absorption interference, Activated Charcoal requires separation from Zypine administration, as it significantly reduces its absorption. Population-specific cautions note that factors associated with decreased oxidative metabolism, such as being an elderly, non-smoking woman, may alter the clearance profile.

Mechanism of Action

Dopamine and Serotonin Receptor Antagonism

Zypine’s core action involves the simultaneous blockade (antagonism) of Dopamine mathbfD2 and Serotonin mathbf5-HT2A receptors, primarily within the brain's mesolimbic and mesocortical pathways. This dual action reduces excessive dopaminergic signaling. The concurrent 5-HT2A blockade, however, influences dopamine release in specific frontal cortical areas, distinguishing its overall neurotransmitter profile from mechanisms that rely solely on D2 antagonism. This central modulation of dopamine and serotonin activity influences neural functions related to emotion, perception, and thought organization, shaping the drug’s overall physiological effect profile.


Multi-Receptor Interactions and Systemic Effects

Zypine also acts as an antagonist on several other targets, including Histamine mathbfH1, Muscarinic cholinergic, and mathbfalpha1-adrenergic receptors. These off-target interactions result in predictable physiological consequences. The antagonism of H1 receptors causes sedation, while blockade of muscarinic receptors leads to anticholinergic effects like dry mouth, which shape the drug’s overall profile.


Modulation of Key Metabolic Cascades

The drug's mechanism extends beyond the cell surface, engaging with intracellular pathways like the PI3K-Akt/MAPK cascade, which are critical for metabolic signaling. This downstream modulation of metabolic signaling contributes to observed physiological changes related to weight gain and the drug's effect on glucose homeostasis.

Dosage and Administration Information

Administration Routes and Dosage Patterns

Zypine (olanzapine) administration is structured around its two approved delivery pathways for acute stabilization and long-term maintenance. The medication is available for oral use as standard tablets and Orally Disintegrating Tablets (ODT), or for parenteral use via deep intramuscular injection (IM).


Oral Dosing and Frequency

Oral therapy is typically administered once daily and may be taken without regard to meals. Standard adult dosing usually begins in the range of 5 mg to 15 mg, with a maintenance target often at 10 mg/day and a maximum oral daily dose of 20 mg. Dose adjustments should occur gradually, respecting minimum time intervals of not less than one week. Population-specific protocols require consideration of a lower oral starting dose of 5 mg/day for older adults and individuals with hepatic or renal impairment.


Intramuscular Use and Special Handling

Administration is strictly limited to the intramuscular route. The short-acting IM injection, intended for acute situations, requires the powder to be reconstituted with sterile water and used immediately. Administration of subsequent doses must respect specific time intervals, with a maximum of three injections per 24 hours. The extended-release IM injection is administered every two or four weeks, a process that mandates a post-injection observation period of at least 2 to 3 hours in a healthcare facility. All forms of Zypine require gradual dose tapering upon conclusion of therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zypine

The research evidence for Zypine (olanzapine) is sourced from official regulatory documents, systematic reviews, and controlled clinical trials. These studies primarily explore how symptoms change over defined time intervals in different diagnostic groups. Research provides context but not individual predictions, and findings describe group patterns observed in the studies, not personal outcomes.

Evidence for use in Schizophrenia

Research was studied for both the patterns of short-term symptom control during an acute episode and research exploring long-term symptom patterns. Study designs included randomized controlled trials (RCTs). Short-term trials typically lasted about six weeks and focused on the measurement of symptom change using validated clinical scales, such as the Positive and Negative Syndrome Scale (PANSS). Longer-term studies monitored the rate of symptom relapse and observed responses over intervals up to a year.

Evidence for use in Bipolar I Disorder

Clinical evaluation was studied across two distinct phases: acute episodes and long-term symptom research. For acute manic or mixed episodes, research examined the measured outcomes related to short-term symptom patterns over three to four weeks. The outcomes examined were the measurements of change recorded on scales like the Young Mania Rating Scale (YMRS).

For long-term symptom research, studies monitored patients over a defined interval, often up to a year, to assess the rate of recurrence of mood episodes (manic, mixed, or depressive). While these studies describe short-term changes and patterns of intermediate stability, long-term effects are not fully established.

What is Still Uncertain About Zypine

Several research limitations persist in the general evidence landscape. Follow-up durations were limited in many acute studies. Comparative evidence against all alternative treatments is lacking in some areas, and studies provide limited insight into long-term functional and quality-of-life outcomes, focusing predominantly on symptom severity scores.

Frequently Asked Questions (FAQ)

Common questions about Zypine (FAQ)


Q: How quickly does Zypine start working (onset of action)?

Studies and official information indicate that the full symptom changes for conditions like schizophrenia or Bipolar I disorder are typically measured over several weeks. Clinical trials for approved uses generally examine outcomes in short-term intervals of approximately three to six weeks.


Q: Is it safe to drink alcohol while taking Zypine?

Regulatory documents state that Zypine should be used carefully in combination with alcohol or other centrally acting drugs. This is because this combination carries a risk of potentiating (increasing) central nervous system effects such as sedation (drowsiness) and orthostatic hypotension (dizziness when standing up).


Q: Will I gain weight while taking Zypine?

According to the official product information, weight gain is a Very Common adverse reaction, meaning it occurred in 10% or more of patients in clinical trials. Official prescribing information recommends regular monitoring of weight during treatment.


Q: Is Zypine safe for people with a history of heart problems?

Official documents describe that caution is warranted in people with known cardiovascular (heart) conditions. This caution is primarily due to the risk of orthostatic hypotension, which is a drop in blood pressure when changing positions that can cause dizziness or fainting.


Q: Can Zypine be used by pregnant or breastfeeding women?

Official labeling states that breastfeeding is not recommended during use of this medicine. Use during the third trimester of pregnancy has been associated with the risk of extrapyramidal or withdrawal symptoms in the newborn.


Q: What age group is Zypine generally prescribed for?

Zypine is established for use in adults and in adolescents aged 13 years and older for approved indications. However, official documents state that the safety and effectiveness have not been established in children younger than 13 years.


Q: Can Zypine cause sexual side effects or changes in libido?

The official safety profile indicates that Zypine has been associated with elevated levels of prolactin (hyperprolactinemia) in the blood. This hormonal change is known to potentially lead to related symptoms, including changes in sex drive or sexual performance.


Q: What is the half-life of Zypine in the body?

Pharmacokinetic studies show that the elimination half-life of Zypine after oral administration is typically in the range of 21 to 54 hours. The average half-life is approximately 30 hours, which is the time it takes for half of the drug to be eliminated from the body.


Q: Is Zypine the same as its generic version in terms of effectiveness?

Regulatory agencies like the FDA consider generic versions containing the active ingredient olanzapine to be bioequivalent. This means that, based on regulatory standards, the generic form is considered comparable to the brand-name product.


Q: How long does Zypine stay in your system after the last dose?

Studies on the drug’s elimination indicate an average half-life of about 30 hours. Given this, the drug generally reaches steady-state concentrations after about one week of daily dosing, which informs the length of time it remains active after the medicine is stopped.


Q: What are the signs of a serious reaction or overdose to Zypine?

Serious adverse reactions that may require immediate care include Neuroleptic Malignant Syndrome (NMS), characterized by high fever, severe muscle stiffness, and changes in mental state. Signs of an overdose may include very severe sedation (potentially leading to a coma), delirium, and cardiac arrhythmias (irregular heart rhythms).


Q: Do I need to get regular blood tests while taking Zypine?

Regulatory documents state that monitoring of certain metabolic and blood factors, such as fasting blood glucose and lipid profiles, should be performed during treatment. Complete blood counts should also be monitored in patients with certain risk factors.


Q: Are there any dietary restrictions or foods to avoid while on Zypine?

Official product information describes the potential for enhanced central nervous system effects when alcohol is used. The documentation also notes that cigarette smoking can increase the clearance of the drug from the body, which may require dose consideration.


Q: Is it possible for Zypine to cause long-term side effects that appear later?

Official warnings include the risk of Tardive Dyskinesia (TD), which is a syndrome of involuntary movements that can potentially be irreversible. TD may develop after months or years of continuous treatment, or in some cases, even after discontinuing the drug.


Q: Does Zypine affect your ability to drive or operate machinery?

Zypine has the potential to impair thinking, judgment, and motor skills, particularly when first starting treatment. Official labeling includes a caution regarding this potential impairment, which is why patients are advised to use care when operating machinery, including automobiles.


Q: Is Zypine considered addictive or habit-forming?

Zypine (olanzapine) is a prescription-only medicine but is not classified as a federally controlled substance in the United States. However, official labeling mandates that therapy must be concluded using a gradual dose tapering, rather than stopping abruptly.


Q: What other prescription medications commonly interact with Zypine?

Interactions are documented with certain medications that affect the CYP1A2 enzyme, such as the inhibitor Fluvoxamine and the inducer Carbamazepine. Additionally, combining it with CNS-acting drugs or parenteral benzodiazepines is restricted or strictly prohibited with the injectable form.


Q: Can Zypine be crushed, split, or chewed?

Official product information is available for both a standard oral tablet and an Orally Disintegrating Tablet (ODT). The ODT form is specifically designed to dissolve rapidly on the tongue without chewing, but the labeling does not contain instructions for crushing or splitting the standard tablet form.


Q: What should I know about generic Zypine before accepting it?

The generic version contains the same active ingredient, olanzapine, and is certified by the FDA as being therapeutically equivalent to the brand-name product. This means the active ingredient is identical, and the generic is required to meet the same regulatory standards for quality and performance.


Q: How does Zypine affect mood or energy levels?

Somnolence (drowsiness) is documented as a Very Common adverse reaction, and dizziness and fatigue are also listed as common side effects. These effects may naturally affect a person's perceived energy levels.


Q: Does Zypine affect blood sugar levels?

Increases in blood glucose are documented as a Very Common adverse reaction. Official warnings highlight the risk of severe hyperglycemia (very high blood sugar) and diabetes mellitus, which is why blood sugar monitoring is recommended during treatment.


Q: Is Zypine a controlled substance?

Zypine (olanzapine) is a prescription-only drug but is not currently listed as a federally controlled substance (Schedule I–V) in the United States or a similar classification by many global authorities.


Q: Can Zypine cause dry mouth or increased thirst?

Dry mouth is listed as a common adverse reaction, and this is linked to the drug's action as an anticholinergic agent. Additionally, increased thirst can be a symptom related to high blood sugar, which is a documented side effect.


Q: Does Zypine affect blood pressure?

Orthostatic hypotension, which is a drop in blood pressure when standing, is listed as a common side effect, particularly during the first few doses. This effect can cause dizziness. Other medications that lower blood pressure may enhance this effect.

How should Zypine be stored and disposed of?

How to Store and Dispose of Zypine?

Zypine (olanzapine) must be stored according to specific regulatory requirements to maintain its stability.

Official Storage Conditions

Storage Requirement Details
Temperature Store at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F).
Protection Keep protected from moisture and light.
Child Safety Store out of the sight and reach of children.
Packaging Orally Disintegrating Tablets (ODT) must remain in the original protective blister pack until administration.

Disposal Instructions

Unused or expired Zypine should be disposed of through a community drug take-back program. If one is not available, the medication must be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container, and discarded in the household trash. The product should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zypine found in:

A-Z Index: